BACKGROUND: Nicotine is responsible for smoking dependence and is mainly metabolised by CYP2A6. Several types of genetic polymorphism of CYP2A6 have been reported, but their relation to smoking habit and chronic obstructive pulmonary disease (COPD) phenotypes has not been fully clarified. METHODS: 203 current or ex-smokers (lifelong cigarette consumption (CC) >/=10 pack years) with subclinical and established COPD phenotypes were clinically evaluated and pulmonary function tests and a chest CT scan were performed (smoker group). The non-smoker group consisted of 123 healthy volunteers. CYP2A6 genotypes were determined in both groups. RESULTS: The percentage of subjects with a CYP2A6del allele (genotype D) was lower in heavy smokers (20.5%, n=88, CC >/=60 pack years) than in light smokers (37.4%, n=115, CC 10-59 pack years, chi(2)=6.8, p=0.01) or non-smokers (36.1%, n=122, chi(2)=6.0, p=0.01); lower in ex-smokers (20.7%, n=111) than in current smokers (41.3%, n=92, chi(2)=10.1, p<0.01); and lower in smokers with a high LAA (low attenuation area) score on the chest CT scan (18.4%, n=76, LAA >/=8.0) than in those with a low LAA score (37.0%, n=127, LAA <8.0, chi(2)=7.8, p<0.01). CONCLUSIONS: Subjects with the CYP2A6del allele tend not to be heavy habitual smokers but can be light habitual smokers. The CYP2A6del polymorphism may inhibit smokers from giving up smoking, but appears to function as a protective factor against the development of pulmonary emphysema independent of smoking habit.
BACKGROUND:Nicotine is responsible for smoking dependence and is mainly metabolised by CYP2A6. Several types of genetic polymorphism of CYP2A6 have been reported, but their relation to smoking habit and chronic obstructive pulmonary disease (COPD) phenotypes has not been fully clarified. METHODS: 203 current or ex-smokers (lifelong cigarette consumption (CC) >/=10 pack years) with subclinical and established COPD phenotypes were clinically evaluated and pulmonary function tests and a chest CT scan were performed (smoker group). The non-smoker group consisted of 123 healthy volunteers. CYP2A6 genotypes were determined in both groups. RESULTS: The percentage of subjects with a CYP2A6del allele (genotype D) was lower in heavy smokers (20.5%, n=88, CC >/=60 pack years) than in light smokers (37.4%, n=115, CC 10-59 pack years, chi(2)=6.8, p=0.01) or non-smokers (36.1%, n=122, chi(2)=6.0, p=0.01); lower in ex-smokers (20.7%, n=111) than in current smokers (41.3%, n=92, chi(2)=10.1, p<0.01); and lower in smokers with a high LAA (low attenuation area) score on the chest CT scan (18.4%, n=76, LAA >/=8.0) than in those with a low LAA score (37.0%, n=127, LAA <8.0, chi(2)=7.8, p<0.01). CONCLUSIONS: Subjects with the CYP2A6del allele tend not to be heavy habitual smokers but can be light habitual smokers. The CYP2A6del polymorphism may inhibit smokers from giving up smoking, but appears to function as a protective factor against the development of pulmonary emphysema independent of smoking habit.
Authors: K Soejima; K Yamaguchi; E Kohda; K Takeshita; Y Ito; H Mastubara; T Oguma; T Inoue; Y Okubo; K Amakawa; H Tateno; T Shiomi Journal: Am J Respir Crit Care Med Date: 2000-04 Impact factor: 21.405
Authors: M Oscarson; R A McLellan; H Gullstén; Q Y Yue; M A Lang; M L Bernal; B Sinues; A Hirvonen; H Raunio; O Pelkonen; M Ingelman-Sundberg Journal: FEBS Lett Date: 1999-04-01 Impact factor: 4.124
Authors: M Miyamoto; Y Umetsu; H Dosaka-Akita; Y Sawamura; J Yokota; H Kunitoh; N Nemoto; K Sato; N Ariyoshi; T Kamataki Journal: Biochem Biophys Res Commun Date: 1999-08-11 Impact factor: 3.575
Authors: P Fernandez-Salguero; S M Hoffman; S Cholerton; H Mohrenweiser; H Raunio; A Rautio; O Pelkonen; J D Huang; W E Evans; J R Idle Journal: Am J Hum Genet Date: 1995-09 Impact factor: 11.025
Authors: R S Caraballo; G A Giovino; T F Pechacek; P D Mowery; P A Richter; W J Strauss; D J Sharp; M P Eriksen; J L Pirkle; K R Maurer Journal: JAMA Date: 1998-07-08 Impact factor: 56.272
Authors: J O'Loughlin; G Paradis; W Kim; J DiFranza; G Meshefedjian; E McMillan-Davey; S Wong; J Hanley; R F Tyndale Journal: Tob Control Date: 2004-12 Impact factor: 7.552
Authors: Jeannine Chan; Tyler Oshiro; Sarah Thomas; Allyson Higa; Stephen Black; Aleksandar Todorovic; Fawzy Elbarbry; John P Harrelson Journal: Drug Metab Dispos Date: 2016-02-05 Impact factor: 3.922
Authors: Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein Journal: Pharmacogenet Genomics Date: 2012-09 Impact factor: 2.089
Authors: Peter J Castaldi; Raúl San José Estépar; Carlos S Mendoza; Craig P Hersh; Nan Laird; James D Crapo; David A Lynch; Edwin K Silverman; George R Washko Journal: Am J Respir Crit Care Med Date: 2013-11-01 Impact factor: 21.405